Evolution of cell therapy for renal cell carcinoma
Abstract Treatment for renal cell carcinoma (RCC) has improved dramatically over the last
decade, shifting from high-dose cytokine therapy in combination with surgical resection of …
decade, shifting from high-dose cytokine therapy in combination with surgical resection of …
Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future
VJ Morel, J Rössler… - Medicinal research reviews, 2024 - Wiley Online Library
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. Histology
separates two main subtypes: embryonal RMS (eRMS; 60%–70%) and alveolar RMS …
separates two main subtypes: embryonal RMS (eRMS; 60%–70%) and alveolar RMS …
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects
One of the major hurdles that has hindered the success of chimeric antigen receptor (CAR) T
cell therapies against solid tumors is on-target off-tumor (OTOT) toxicity due to sharing of the …
cell therapies against solid tumors is on-target off-tumor (OTOT) toxicity due to sharing of the …
Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model
Y Wang, JW Cho, G Kastrunes, A Buck, C Razimbaud… - Iscience, 2024 - cell.com
One of the major barriers that have restricted successful use of chimeric antigen receptor
(CAR) T cells in the treatment of solid tumors is an unfavorable tumor microenvironment …
(CAR) T cells in the treatment of solid tumors is an unfavorable tumor microenvironment …